Effects of Insulin Treatment in Type 2 Diabetic Patients on Intracellular Lipid Content in Liver and Skeletal Muscle
- Christian Anderwald,
- Elisabeth Bernroider,
- Martin Krs̆s̆ák,
- Harald Stingl,
- Attila Brehm,
- Martin G. Bischof,
- Peter Nowotny,
- Michael Roden and
- Werner Waldhäusl
- From the Division of Endocrinology and Metabolism, Department of Internal Medicine III, University of Vienna, Vienna, Austria
Abstract
Insulin resistance is frequently associated with increased lipid content in muscle and liver. Insulin excess stimulates tissue lipid accumulation. To examine the effects of insulin and improved glycemia on insulin sensitivity and intracellular lipids, we performed stepped (1, 2, and 4 mU · min−1 · kg−1) hyperinsulinemic-euglycemic clamps in eight type 2 diabetic and six nondiabetic control subjects at baseline and after 12 and 67 h of insulin-mediated near-normoglycemia (118 ± 7 mg/dl). Intrahepatocellular lipids (IHCLs) and intramyocellular lipids (IMCLs) of soleus (IMCL-S) and tibialis anterior muscle (IMCL-TA) were measured with 1H nuclear magnetic resonance spectroscopy. At baseline, nondiabetic subjects had an approximate twofold higher insulin sensitivity (P < 0.02) and lower IHCLs than diabetic patients (5.8 ± 1.2 vs. 18.3 ± 4.2%, P < 0.03), in whom IMCL-TA negatively correlated with insulin sensitivity (r = −0.969, P < 0.001). After a 67-h insulin infusion in diabetic patients, IMCL-S and IHCLs were increased (P < 0.05) by ∼36 and ∼18%, respectively, and correlated positively with insulin sensitivity (IMCL-S: r = 0.982, P < 0.0005; IHCL: r = 0.865, P < 0.03), whereas fasting glucose production, measured with d-[6,6-2H2]glucose, decreased by ∼10% (P < 0.04). In conclusion, these results indicate that IMCLs relate to insulin resistance in type 2 diabetic patients at baseline and that insulin-mediated near-normoglycemia for ∼3 days reduces fasting glucose production but stimulates lipid accumulation in liver and muscle without affecting insulin sensitivity.
Footnotes
-
Address correspondence and reprint requests to Michael Roden, Division of Endocrinology and Metabolism, Department of Internal Medicine III, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. E-mail: michael.roden{at}akh-wien.ac.at.
Received for publication 13 December 2001 and accepted in revised form 3 July 2002.
C-D1, study day 1 for control subjects; EGP, endogenous glucose production; FFA, free fatty acid; IHCL, intrahepatocellular lipid; IMCL, intramyocellular lipid; IMCL-S, IMCLs in soleus muscle; IMCL-TA, IMCLs in tibialis anterior muscle; MCR, metabolic clearance rate; MPE, mole percent excess; NMR, nuclear magnetic resonance; P-D1, study day 1 for type 1 diabetic patients; P-D2, study day 2 for type 2 diabetic patients; P-D3, study day 3 for type 2 diabetic patients; P-D6, study day 6 for type 2 diabetic patients.
- DIABETES











